BSE: 531726 | NSE: PANCHSHEEL | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Panchsheel Organics Ltd is a good quality company.
The key valuation ratios of Panchsheel Organics Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Panchsheel Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 14.3% | 18.5% | 19.7% | 18.2% | 17.8% | 20.3% | 18.6% | 24.6% | 25.6% | 16.9% | - |
| Value Creation Index ⓘ | 0.0 | 0.3 | 0.4 | 0.3 | 0.3 | 0.5 | 0.3 | 0.8 | 0.8 | 0.2 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 35.8 | 40.4 | 40.1 | 42.4 | 48.2 | 50.5 | 49.5 | 69 | 103 | 105 | 110 |
| Sales YoY Gr. | - | 12.8% | -0.7% | 5.7% | 13.8% | 4.7% | -2% | 39.5% | 49.5% | 2% | - |
| Adj EPS ⓘ | 1.9 | 2.9 | 3.2 | 3.7 | 4 | 5.3 | 5 | 8.3 | 11.9 | 10.7 | 10.8 |
| YoY Gr. | - | 51.3% | 11.9% | 15.6% | 8.9% | 32.5% | -7.1% | 67.9% | 43.1% | -10.2% | - |
| BVPS (₹) ⓘ | 18.5 | 20.8 | 23.4 | 26.9 | 30.4 | 35.2 | 39.6 | 47.3 | 76.1 | 94.9 | 97.5 |
| Adj Net Profit ⓘ | 1.9 | 2.9 | 3.2 | 3.7 | 4 | 5.4 | 5 | 8.4 | 14.1 | 14.1 | 14 |
| Cash Flow from Ops. ⓘ | 1.1 | 3 | 4.6 | 3.1 | 2.5 | 4.6 | 4.9 | -1.8 | 0 | 9.6 | - |
| Debt/CF from Ops. ⓘ | 5.9 | 1.7 | 1.5 | 1.9 | 2 | 0.9 | 0.8 | -2.4 | 132.5 | 0.7 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 12.7% | 16.9% | 28.6% | 2% | ||||
| Adj EPS ⓘ | 21.3% | 21.6% | 29.3% | -10.2% | ||||
| BVPSⓘ | 20% | 25.6% | 33.9% | 24.7% | ||||
| Share Price | 29.1% | 51% | 30.3% | 17.4% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 10.5 | 14.6 | 14.5 | 14.7 | 14.1 | 16.3 | 13.3 | 19.2 | 19.6 | 12.8 | 11.2 |
| Op. Profit Mgn % ⓘ | 13.4 | 14 | 16.7 | 16.4 | 14.4 | 17.1 | 17.4 | 18.6 | 19.2 | 18 | 17.4 |
| Net Profit Mgn % ⓘ | 5.3 | 7.1 | 8 | 8.8 | 8.4 | 10.6 | 10.1 | 12.1 | 13.6 | 13.4 | 12.9 |
| Debt to Equity ⓘ | 0.4 | 0.2 | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Working Cap Days ⓘ | 256 | 231 | 250 | 285 | 280 | 287 | 330 | 292 | 307 | 395 | 156 |
| Cash Conv. Cycle ⓘ | 151 | 153 | 165 | 183 | 181 | 188 | 189 | 161 | 162 | 188 | 105 |
Sales growth is growing at healthy rate in last 3 years 28.59%
Net Profit is growing at healthy rate in last 3 years 29.25%
Return on Equity has declined versus last 3 years average to 11.20%
Sales growth is not so good in last 4 quarters at 4.48%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 10.8 | - |
| TTM Sales (₹ Cr.) | 110 | - |
| BVPS (₹.) ⓘ | 97.5 | - |
| Reserves (₹ Cr.) ⓘ | 115 | - |
| P/BV ⓘ | 2.25 | - |
| PE ⓘ | 20.24 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 173.00 / 309.90 |
| All Time Low / High (₹) | 0.90 / 425.55 |
| Market Cap (₹ Cr.) | 288 |
| Equity (₹ Cr.) | 13.2 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 36 | 40 | 40 | 42 | 48 | 50 | 49 | 69 | 103 | 105 |
| Operating Expenses ⓘ | 31 | 35 | 33 | 36 | 41 | 42 | 41 | 56 | 83 | 86 |
| Manufacturing Costs | 2 | 2 | 3 | 2 | 2 | 4 | 6 | 10 | 9 | 8 |
| Material Costs | 24 | 27 | 25 | 27 | 32 | 30 | 28 | 39 | 65 | 68 |
| Employee Cost | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 6 | 7 |
| Other Costs ⓘ | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 |
| Operating Profit ⓘ | 5 | 6 | 7 | 7 | 7 | 9 | 9 | 13 | 20 | 19 |
| Operating Profit Margin (%) | 13.4% | 14.0% | 16.7% | 16.2% | 14.4% | 16.9% | 17.4% | 18.6% | 19.2% | 18.0% |
| Other Income ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Interest ⓘ | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 3 | 4 | 5 | 5 | 6 | 7 | 7 | 11 | 19 | 19 |
| Tax ⓘ | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 5 | 5 |
| Profit After Tax | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 8 | 14 | 14 |
| PAT Margin (%) | 5.3% | 7.5% | 8.0% | 8.7% | 8.4% | 10.5% | 10.1% | 12.1% | 13.6% | 13.4% |
| Adjusted EPS (₹) | 1.9 | 3.0 | 3.2 | 3.7 | 4.0 | 5.3 | 5.0 | 8.3 | 11.9 | 10.7 |
| Dividend Payout Ratio (%) | 13% | 17% | 16% | 0% | 0% | 0% | 20% | 6% | 30% | 31% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 19 | 21 | 23 | 27 | 30 | 35 | 40 | 47 | 90 | 125 |
| Share Capital ⓘ | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 10 | 12 | 13 |
| Reserves ⓘ | 13 | 16 | 18 | 22 | 25 | 30 | 35 | 37 | 78 | 112 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 6 | 4 | 6 | 5 | 5 | 4 | 3 | 4 | 5 | 6 |
| Long Term Debt | 2 | 3 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 |
| Short Term Debt | 4 | 2 | 5 | 5 | 4 | 4 | 2 | 3 | 5 | 6 |
| Trade Payables | 5 | 8 | 6 | 9 | 6 | 9 | 12 | 17 | 16 | 21 |
| Others Liabilities ⓘ | 3 | 4 | 4 | 6 | 4 | 4 | 5 | 7 | 14 | 11 |
| Total Liabilities ⓘ | 33 | 37 | 39 | 47 | 45 | 53 | 59 | 75 | 124 | 163 |
Fixed Assets | ||||||||||
| Gross Block | 15 | 17 | 19 | 10 | 11 | 11 | 13 | 14 | 17 | 24 |
| Accumulated Depreciation | 8 | 10 | 11 | 3 | 4 | 5 | 6 | 7 | 9 | 11 |
| Net Fixed Assetsⓘ | 7 | 7 | 8 | 7 | 7 | 6 | 7 | 7 | 8 | 14 |
| CWIP ⓘ | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 6 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Inventories | 10 | 12 | 13 | 14 | 15 | 15 | 19 | 25 | 32 | 40 |
| Trade Receivables | 14 | 15 | 15 | 20 | 18 | 23 | 19 | 33 | 39 | 39 |
| Cash Equivalents | 1 | 1 | 1 | 0 | 1 | 2 | 4 | 2 | 4 | 22 |
| Others Assetsⓘ | 1 | 1 | 1 | 4 | 4 | 5 | 8 | 7 | 38 | 39 |
| Total Assets ⓘ | 33 | 37 | 39 | 47 | 45 | 53 | 59 | 75 | 124 | 163 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 1 | 3 | 5 | 3 | 2 | 5 | 5 | -2 | 0 | 10 |
| PBT ⓘ | 3 | 5 | 6 | 5 | 6 | 7 | 7 | 11 | 19 | 19 |
| Adjustment ⓘ | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 |
| Changes in Working Capital ⓘ | -2 | -2 | 0 | -1 | -3 | -2 | -1 | -12 | -14 | -3 |
| Tax Paid ⓘ | -2 | -1 | -2 | -2 | -2 | -2 | -2 | -2 | -6 | -6 |
| Cash Flow From Investing Activity ⓘ | -1 | -2 | -3 | -1 | -1 | -3 | -1 | 0 | -34 | -7 |
| Capex | -1 | -2 | -2 | -1 | -1 | 0 | -2 | -2 | -4 | -10 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | -2 | 1 | 1 | -32 | 0 |
| Others ⓘ | 0 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Cash Flow From Financing Activityⓘ | 0 | -1 | -1 | -2 | -2 | -1 | -1 | -1 | 36 | 16 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 |
| Net Proceeds from Borrowing ⓘ | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest Paid ⓘ | -1 | -1 | 0 | -1 | 0 | 0 | 0 | 0 | -1 | 0 |
| Dividend Paid ⓘ | 0 | -1 | -1 | 0 | 0 | 0 | -1 | -1 | -4 | -4 |
| Others ⓘ | 0 | 0 | 0 | -1 | 0 | 0 | -1 | 0 | 8 | 20 |
| Net Cash Flow ⓘ | 0 | -1 | 0 | 0 | 0 | 1 | 3 | -2 | 1 | 18 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 10.55 | 15.43 | 14.48 | 14.57 | 14.05 | 16.08 | 13.35 | 19.19 | 20.52 | 13.14 |
| ROCE (%) | 14.28 | 18.51 | 19.66 | 18.21 | 17.77 | 20.31 | 18.6 | 24.61 | 25.61 | 16.87 |
| Asset Turnover Ratio | 1.08 | 1.18 | 1.08 | 0.99 | 1.05 | 1.03 | 0.88 | 1.03 | 1.03 | 0.73 |
| PAT to CFO Conversion(x) | 0.5 | 1 | 1.67 | 0.75 | 0.5 | 1 | 1 | -0.25 | 0 | 0.71 | Working Capital Days |
| Receivable Days | 137 | 125 | 131 | 149 | 143 | 147 | 153 | 136 | 126 | 136 |
| Inventory Days | 98 | 95 | 107 | 113 | 107 | 108 | 126 | 116 | 102 | 125 |
| Payable Days | 107 | 89 | 101 | 100 | 89 | 95 | 137 | 134 | 92 | 100 |
Panchsheel Organics, incorporated in the year 1989, is a part of the Pharmaceutical Division of the Turakhia Brothers Group. Turakhia Brothers was founded in 1975 in the Mumbai, India. The Turakhia Group, promoters of the company, are engaged in the import-export trade of pharmaceutical raw materials since the past 25 years.
Panchsheel exports bulk actives to over 60 countries mainly in Europe, South East Asia, Japan and Latin America. The company's inherent strength lies in identifying relevant bulk drugs and selling them at affordable prices across the world.
Skilled people, modern equipment and broad experience contribute to the strength of Panchsheel Organics. Skilled production teams assure flexibility, efficiency and consistent standard in drugs manufacturing.
The R & D division of Panchsheel backed with experienced, highly qualified teams provide sophisticated innovative solutions. Skilled production teams assure flexibility, efficiency and consistent standard in chemical manufacturing.
The current practices at Panchsheel are adherence to high quality and safety standards as well as full compliance with GMP procedures. The gaseous emissions are properly controlled and waste water is treated properly so as to ensure compliance with local and international risk, minimizing damage to persons and environment.
Panchsheel has free capacity in its five production sites in all over India. This capacity is would be used by interested companies for development and custom synthesis on strictly confidential terms.
Some of the basic operations carried out by Panchsheel are:
Product range of the company includes: Bulk Drugs - Alendronate Sodium Trihydrate, Isoxsuprine HCL, Alprazolam, Itraconazole Pellets 22%, Amitriptyline HCL BP/USP, Ketoconazole BP/USP, Amlodipine Besylate etc.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
